

**Notification Under Executive Order 12372**

This program is covered under E.O. 12372, "Intergovernmental Review of Federal Programs" and 45 CFR part 100, "Intergovernmental Review of Department of Health and Human Services Programs and Activities." However, since units of local governments are not funded in Fiscal Year 2003, the review and comment provisions of the Executive Order and part 100 do not apply for fiscal year 2003.

**Paperwork Reduction Act**

In accordance with the Paperwork Reduction Act of 1980 (Pub. L. 96-511), the application requirements contained in this notice have been approved by the Office of Management and Budget under control number 0348-0043.

**TABLE I.—FY 2003 TENTATIVE ALLOCATIONS FOR ELECTION ASSISTANCE FOR INDIVIDUALS WITH DISABILITIES**

State	FY 2003 tentative allotments
Alabama .....	185,341
Alaska .....	100,000
American Samoa .....	100,000
Arizona .....	209,686
Arkansas .....	109,029
California .....	1,371,756
Colorado .....	178,308
Connecticut .....	142,841
Delaware .....	100,000
District of Columbia .....	100,000
Florida .....	687,278
Georgia .....	335,237
Guam .....	100,000
Hawaii .....	100,000
Idaho .....	100,000
Illinois .....	511,102
Indiana .....	251,048
Iowa .....	122,161
Kansas .....	110,057
Kentucky .....	169,755
Louisiana .....	181,021
Maine .....	100,000
Maryland .....	219,527
Massachusetts .....	270,154
Michigan .....	409,083
Minnesota .....	202,382
Mississippi .....	115,296
Missouri .....	232,185
Montana .....	100,000
Nebraska .....	100,000
Nevada .....	100,000
New Hampshire .....	100,000
New Jersey .....	352,485
New Mexico .....	100,000
New York .....	795,936
North Carolina .....	339,029
North Dakota .....	100,000
Oregon .....	143,454
Ohio .....	471,600
Oklahoma .....	142,530
Pennsylvania .....	521,409
Puerto Rico .....	151,345

**TABLE I.—FY 2003 TENTATIVE ALLOCATIONS FOR ELECTION ASSISTANCE FOR INDIVIDUALS WITH DISABILITIES—Continued**

State	FY 2003 tentative allotments
Rhode Island .....	100,000
South Carolina .....	167,271
South Dakota .....	100,000
Tennessee .....	240,958
Texas .....	833,749
Utah .....	100,000
Vermont .....	100,000
Virgin Islands .....	100,000
Virginia .....	297,522
Washington .....	244,039
West Virginia .....	100,000
Wisconsin .....	185,426
Wyoming .....	100,000
Total .....	13,000,000

Dated: May 14, 2003.

**Patricia A Morrissey,**  
*Commissioner, Administration on Developmental Disabilities*  
 [FR Doc. 03-13394 Filed 5-28-03; 8:45 am]  
**BILLING CODE 4184-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Gastrointestinal Drugs Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Gastrointestinal Drugs Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on June 25 and 26, 2003, from 8:30 a.m. to 5 p.m.

*Location:* Marriott Washingtonian Center, The Ballrooms, 9751 Washingtonian Blvd., Gaithersburg, MD, 301-590-0044.

*Contact Person:* Thomas H. Perez, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-6758, or e-mail: PerezT@cder.fda.gov, or FDA Advisory Committee Information

Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12538. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* On June 25, 2003, the committee will discuss new drug application (NDA) 21-597, SEROSTIM (somatropin), Serono, Inc., for the treatment of short bowel syndrome in patients receiving specialized nutritional support. SEROSTIM therapy should be used in conjunction with optimal management of short bowel syndrome. On June 26, 2003, the committee will discuss NDA 21-525, PHOTOFRIN (porfimer sodium), Axcan Scandipharma, Inc. Photodynamic therapy with PHOTOFRIN is indicated for the ablation of high-grade dysplasia in Barrett's esophagus among patients who refuse esophagectomy and who are in overall good health.

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by June 16, 2003. Oral presentations from the public will be scheduled between 1 p.m. and 2 p.m. on both days. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before June 16, 2003, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Thomas H. Perez at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: May 22, 2003.

**Peter J. Pitts,**  
*Associate Commissioner for External Relations.*

[FR Doc. 03-13318 Filed 5-28-03; 8:45 am]

**BILLING CODE 4160-01-S**